anti-CD19 CAR T-cells with IL-12 (FamiCordTx)

N/A

Report date: 2025/06/11 10:58:00

Base Information

Drug Nameanti-CD19 CAR T-cells with IL-12 (FamiCordTx)

Drug Alias Nameanti-CD19 CAR T-cell therapy/IL-12 (FamiCordTx)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-12 modulatorsB-lymphocyte antigen CD19 modulatorsImmunostimulants +[4]

TargetsInterleukin-12B-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFamiCordTx SA

China Registration ClassN/A

Develop Information

Active CompaniesFamiCordTx SA

Inactive CompaniesN/A

Active IndicationsLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A